KOSPIBiotech & Pharma170900

Dong-A ST

₩33,350▼ 2.49%2026-11-18 close
Market Cap
₩324.4B
Turnover
₩300M
Volume
8.6K
Shares out.
9.7M
PER
—
PBR
0.5×
EPS
-₩767
Dividend Yield
2.08%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩700 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Grows, Margins Lag; Pipeline Data Ahead

Dong-A ST's revenue rose through 2025 on in-licensed and overseas products, but its operating margin fell from 2.6% in 2022 to 0.1% in 2025, and profitability recovery and obesity pipeline readouts are the next items to track.

  1. 1

    Revenue reached KRW 808.8 billion in 2025, up 15.9% year on year, and has risen for three straight years from 2023 to 2025.

  2. 2

    Operating profit turned positive at KRW 623 million in 2025, but the net loss attributable to controlling shareholders widened to KRW 28.6 billion.

  3. 3

    Over the last four quarters (Q4 2025 to Q3 2026), the net loss attributable to controlling shareholders totaled KRW 6.78 billion, while Q3 2026 operating profit of KRW 18 billion rose 28.5% year on year.

  4. 4

    Brokerage target prices moved lower in the second half of 2026, and analysts cite high-margin products and new drug results as conditions for a re-rating.

  5. 5

    Topline results at 16 weeks for the obesity candidate DA-1726 are scheduled for Q4 2026, and 24-week results are slated for Q1 2027.

02

Business structure

Dong-A ST is a prescription drug maker spun off from the former Dong-A Pharmaceutical in 2013 and is an affiliate of Dong-A Socio Holdings.

Its own products include Stiren, Zydena, Motiriton and Sugalon, alongside in-licensed items such as growth hormone and Gaster, and production runs at its Cheonan, Daegu and Songdo campuses. The company reports three segments: ETC (prescription drugs), overseas business and digital healthcare.

On a separate-financial-statement basis, ETC sales in Q2 2026 were KRW 148.6 billion, up 15.2% year on year. Overseas sales in the same quarter were KRW 46.9 billion, up 20.9%, supported by Bacchus and darbepoetin alfa. Digital healthcare sales were KRW 3.2 billion, up 208.0%, led by the HiCardi wearable ECG monitor.

In-licensed products such as Jakubo, Diperelin, Tanamin and Elidel cream contributed to ETC growth in Q3 2026. Overseas sales were hurt in Q1 2026 by the prolonged Cambodia-Thailand dispute, which reduced Cambodia-linked sales, and beverage sales including Bacchus fell again in Q3.

The company also signed an exclusive sales deal for NeuroGait, an AI-based gait analysis solution. As in-licensed products grow, cost of sales rises; iM Securities said in a November 2025 report that cost ratios would edge up but profitability gains from revenue growth would be larger.

Among listed pharma peers, the company is compared with prescription-focused firms such as Yuhan and Hanmi Pharm, and the weight of its own drug pipeline remains a central question for market valuation.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩215.9B₩14B6.5%
2025Q4₩216.8B-₩2.7B−1.3%
2026Q1₩203.6B₩7.8B3.8%
2026Q2₩224.7B₩6.3B2.8%
2026Q3₩222.7B₩18B8.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩635.4B₩16.7B₩13.6B2.6%2.0%67.8%
2023₩664B₩11.2B₩11.1B1.7%1.7%85.0%
2024₩697.9B-₩25B-₩1.2B−3.6%−0.2%96.3%
2025₩808.8B₩600M-₩28.6B0.1%−4.4%110.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue rose from KRW 635.4 billion in 2022 to KRW 664 billion in 2023 and KRW 697.9 billion in 2024, reaching KRW 808.8 billion in 2025, up 15.9% that year and the largest year in the 2022 to 2025 period. Revenue has increased for three consecutive years from 2023 to 2025.

Operating profit fell from KRW 16.7 billion in 2022 to KRW 11.2 billion in 2023, down 33.0%, then turned into an operating loss of KRW 25 billion in 2024 before returning to a KRW 623 million operating profit in 2025.

The operating margin moved from 2.6% in 2022 to 1.7% in 2023, -3.6% in 2024 and 0.1% in 2025, so revenue growth did not translate into margin gains.

Cost ratios are cited as a driver, and iM Securities said in a November 2025 report that the cost ratio would edge up with in-licensed products, but revenue-driven profitability gains would be larger.

Net income attributable to controlling shareholders fell from KRW 13.6 billion in 2022 to KRW 11.1 billion in 2023, down 17.9%, then became a loss of KRW 1.22 billion in 2024 and widened to a loss of KRW 28.6 billion in 2025, marking two consecutive loss years from 2024 to 2025.

Net loss including non-controlling interests was KRW 37.6 billion in 2025.

Quarterly, an operating loss of KRW 2.74 billion in Q4 2025 turned into an operating profit of KRW 7.76 billion in Q1 2026, followed by KRW 6.29 billion in Q2, down 18.9% quarter on quarter, and KRW 18 billion in Q3, up 185.7% quarter on quarter and 28.5% year on year.

The net loss attributable to controlling shareholders in Q3 2026 was KRW 6.23 billion, a swing to loss year on year, and the gap between operating profit and net loss points to below-the-line items such as non-operating results or taxes, which the quarterly filing's income statement should clarify.

Daol Investment & Securities attributed Q3 2026 profitability gains to deferred R&D spending and lower selling and administrative costs, and expected margins to soften in Q4 as deferred R&D is spent. Operating cash flow moved from an outflow of KRW 11.8 billion in 2024 to an inflow of KRW 27.8 billion in 2025.

Company press releases use separate-financial-statement figures, which differ from the regulatory filing amounts used here.

05

Industry analysis

Dong-A ST sells both in-licensed and own-developed products, so its revenue growth depends largely on the expansion of in-licensed items.

Jakubo has been recognized as a fast-growing product since being reflected in revenue from Q3 2024. iM Securities highlighted that the company holds candidates in areas that are major market trends, such as obesity and dementia.

Samsung Securities, in an August 2026 report, said the market's valuation discount on the company's low operating margin is offsetting the value of its pipeline. Kiwoom Securities, in an October 2026 report, said the stock market wants visibility on high-margin products and R&D momentum.

Overseas, darbepoetin alfa's share in Japan is expanding, while beverage exports such as Bacchus are affected by economic slowdown and the regional dispute. Among peers, Dong-A ST is compared with listed pharma companies that combine new drugs and in-licensed products, such as Yuhan and Hanmi Pharm.

Brokers' assessments focus more on company-specific clinical results and margin improvement than on sector indicators.

06

Outlook

In its Q2 2026 results announcement, the company said it plans to launch the new HiCardi M350 in the second half to expand its digital healthcare business. Daol Investment & Securities expects the HiCardi M350 launch in Q4 2026.

The epilepsy drug Xcopri, whose domestic rights were in-licensed, is scheduled for launch in November 2026, and price negotiations are ongoing. Daol said the company targets annual sales above KRW 40 billion within three to four years after launch.

In the pipeline, DA-1241, for MASH and type 2 diabetes, has completed a global Phase 2a trial. The obesity candidate DA-1726 is in Part 3 of a global Phase 1 study, and its dosing period was extended from 16 to 24 weeks, with 16-week topline results expected in Q4 2026 and 24-week results in Q1 2027.

The tau aggregation inhibitor DA-7503 and the immuno-oncology candidate DA-4505 are planned for Phase 1 trials in Korea. These timelines come from company statements and brokerage reports, and the actual effect will become clear only when the results are released.

The next regular filing, the 2026 annual report, must be submitted within 90 days after fiscal year-end, so the deadline is the end of March 2027, and it will show the full-year operating margin, cash flow and debt ratio trends.

07

Valuation

PER
—
PBR
0.5×
ROE
-1.1%
EPS
-₩767
BPS
₩66,285
Dividend per share
₩700

Over the last four quarters the net loss attributable to controlling shareholders totaled KRW 6.78 billion, so the price-to-earnings ratio is not calculated. The price-to-book ratio is below 1 times, meaning the share price sits well below book value per share.

Shareholders' equity at the end of 2025 was KRW 671.6 billion, of which KRW 642.7 billion belonged to controlling shareholders, and this base is used when comparing book value with market value.

Among brokers, Samsung Securities proposed a target of KRW 50,000 on August 11, 2026, Kiwoom Securities proposed KRW 50,000 on October 19, 2026, and Daol Investment & Securities proposed KRW 60,000 on October 28, 2026.

Samsung Securities said the market's valuation discount on the low operating margin is offsetting the value of the pipeline and could ease if R&D momentum becomes visible.

Kiwoom Securities said that even with cost-efficient results, a full re-rating requires growth from high-margin products and clearer new drug results.

Over several years, the operating margin fell from 2.6% in 2022 to 0.1% in 2025 and the debt ratio rose from 67.8% to 110.2%, so the pace of profit recovery and financial burden are read together.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Growth across three segments

On a separate-statement basis, Q2 2026 ETC sales rose 15.2% to KRW 148.6 billion, overseas sales rose 20.9% to KRW 46.9 billion, and digital healthcare rose 208.0% to KRW 3.2 billion. ETC sales in Q3 2026 rose 7.3% to KRW 155.9 billion. Annual revenue has increased for three consecutive years from 2023 to 2025.

Operating profit back in the black

Q3 2026 operating profit was KRW 18 billion, up 28.5% year on year. Daol Investment & Securities attributed the profitability gain to deferred R&D spending and lower selling and administrative costs. Operating profit has been positive in Q1, Q2 and Q3 2026.

Concentrated pipeline events

DA-1241, for MASH and type 2 diabetes, has completed a global Phase 2a trial. The obesity candidate DA-1726 is in Part 3 of a global Phase 1 study, with 16-week topline results scheduled for Q4 2026. Samsung Securities said visible R&D momentum, including these results, could ease the market's discount.

09

Bear factors

Profitability is still thin

The operating margin was 0.1% in 2025, and the net loss attributable to controlling shareholders was KRW 28.6 billion. Over the last four quarters, that net loss totaled KRW 6.78 billion. The Q3 2026 operating profit did not eliminate the net loss attributable to controlling shareholders.

Cost ratios on in-licensed products and overseas weakness

As in-licensed products grow, cost of sales rises, and iM Securities also flagged a modest increase in cost ratios. Overseas sales were hit by the prolonged Cambodia-Thailand dispute, and Q3 2026 overseas sales fell 3.9% to KRW 39.2 billion. This aligns with the margin decline from 2.6% in 2022 to 0.1% in 2025.

Debt burden and cash flow

The debt ratio rose from 67.8% in 2022 to 110.2% in 2025, with total liabilities of KRW 740.4 billion and total equity of KRW 671.6 billion at the end of 2025.

Operating cash flow improved from an outflow of KRW 11.8 billion in 2024 to an inflow of KRW 27.8 billion in 2025, and whether this continues must be confirmed in the 2026 annual report.

10

Risk factors

Clinical and R&D results

If pipeline clinical results fall short of expectations, the valuation discount could persist. The obesity candidate's dosing period was extended from 16 to 24 weeks, pushing the final readout into Q1 2027. Depending on the results, the valuation of the new drug candidates could change significantly.

Pricing and dependence on in-licensed products

Xcopri's price negotiations are ongoing, so the timing and scale of sales after launch could differ from plans. As in-licensed products such as Jakubo take a larger share, cost ratios and profit volatility could increase. If in-licensed products underperform, the revenue growth trend could weaken.

Overseas and beverage demand

Beverage products such as Bacchus were affected by economic slowdown and lower exports. If the Cambodia-Thailand dispute persists, the recovery of overseas sales could be delayed. Whether the expansion of darbepoetin alfa's share in Japan offsets this in part needs to be watched.

11

What to watch next

  1. November 2026

    Domestic launch of the epilepsy drug Xcopri and the outcome of price negotiations. This is the point to confirm the actual launch and how quickly it feeds into ETC sales.

  2. Q4 2026

    Topline results at 16 weeks from the global trial of the obesity candidate DA-1726. This is the first point where the pipeline assessment can be checked against data.

  3. Q4 2026

    The launch of HiCardi M350 and the pace of R&D spending. Daol Investment & Securities expected margins to soften in this period, so actual operating margins can be compared against that view.

  4. Q1 2027

    24-week results for DA-1726. These are the longer-term data that follow the extension of the dosing period.

  5. End of March 2027 (regular filing deadline)

    The 2026 annual report. It is the point to confirm full-year operating margin, net income attributable to controlling shareholders, cash flow and debt ratio, including Q4, from the filed figures.

12

Overall view

Dong-A ST's revenue grew from KRW 635.4 billion in 2022 to KRW 808.8 billion in 2025, showing continued top-line expansion. However, the operating margin fell from 2.6% in 2022 to 0.1% in 2025, and the net loss attributable to controlling shareholders has persisted for two consecutive years from 2024.

Q3 2026 operating profit of KRW 18 billion, up 28.5% year on year, signals a profitability recovery, yet the net loss attributable to controlling shareholders of KRW 6.23 billion in the same quarter means the loss has not fully disappeared.

On the bullish side, growth in in-licensed products and digital healthcare and obesity clinical results stand out. On the bearish side, cost ratio pressure, a debt ratio of 110.2% at the end of 2025, and weakness in overseas beverage sales are the main points.

The next checkpoints are the Xcopri launch in November 2026, 16-week topline results for the obesity candidate in Q4 2026, and the 2026 annual report at the end of March 2027. Revenue and the pipeline have many datable milestones, while the durability of profits and cash flow will be assessed through full-year filings.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. kor.theasian.asia
  3. discoverynews.kr
  4. insightkorea.co.kr
  5. kndaily.co.kr
  6. asiatime.co.kr
  7. kormedi.com
  8. m.news.nate.com
  9. newsway.co.kr
  10. newspim.com
  11. newspim.com
  12. hankyung.com
  13. m.news.nate.com
  14. m.thinkpool.com
  15. m.thinkpool.com
  16. news.nate.com
  17. press9.kr
  18. etoday.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis